Press "Enter" to skip to content

New patent for Boehringer Ingelheim drug JARDIANCE

0
Copyright © DrugPatentWatch. Originally published at New patent for Boehringer Ingelheim drug JARDIANCE

Annual Drug Patent Expirations for JARDIANCE
Annual Drug Patent Expirations for JARDIANCE

Jardiance is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from four suppliers. There are six patents protecting this drug and one Paragraph IV challenge.

JARDIANCE drug price trends.

Drug patent litigation for JARDIANCE.

This drug has two hundred and five patent family members in forty-four countries.

The generic ingredient in JARDIANCE is empagliflozin. Four suppliers are listed for this compound. Additional details are available on the empagliflozin profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Boehringer Ingelheim drug JARDIANCE
    Get the DrugPatentWatch Daily Briefing

    ✓ Patent Expirations and Generic Entry

    ✓ Insightful Articles & Case Studies

    ✓ Patent Litigation & Challenges

    ✓ 505(b)(2) & Biosimilars

    ✓ Industry Trends

    DrugPatentWatch - Make Better Decisions